 |
| 07-Oct-09 | Reiterated |
UBS |
Neutral |
$17 → $23 |
|
| 08-Sep-09 | Upgrade |
Robert W. Baird |
Neutral → Outperform |
$16 → $30 |
|
| 08-Sep-09 | Reiterated |
ThinkEquity |
Buy |
$18 → $29 |
|
| 21-Apr-09 | Reiterated |
UBS |
Buy |
$25 → $10 |
|
| 18-Mar-09 | Initiated |
Wedbush Morgan |
Buy |
$18 |
|
| 03-Mar-09 | Upgrade |
Roth Capital |
Sell → Hold |
|
|
| 17-Feb-09 | Reiterated |
JMP Securities |
Mkt Perform |
$25 → $20 |
|
| 27-Jan-09 | Initiated |
ThinkEquity |
Buy |
$20 |
|
| 15-Dec-08 | Reiterated |
JMP Securities |
Mkt Outperform |
$35 → $25 |
|
| 05-Dec-08 | Initiated |
Roth Capital |
Sell |
|
|
| 30-Oct-08 | Initiated |
Merriman Curhan Ford |
Buy |
|
|
| 29-Oct-08 | Initiated |
Cowen & Co |
Outperform |
|
|
| 21-Oct-08 | Initiated |
Lazard Capital |
Buy |
$27 |
|
| 28-Jul-08 | Initiated |
Leerink Swann |
Outperform |
|
|
| 21-May-08 | Initiated |
Pacific Growth Equities |
Buy |
|
|
| 16-Apr-08 | Initiated |
Robert W. Baird |
Neutral |
$21 |
|
| 02-Apr-08 | Upgrade |
UBS |
Neutral → Buy |
|
|
| 11-Mar-08 | Initiated |
Merriman Curhan Ford |
Buy |
|
|
| 19-Feb-08 | Downgrade |
UBS |
Buy → Neutral |
|
|
| 29-Jan-08 | Initiated |
JMP Securities |
Mkt Outperform |
|
|
|
|
| 05-Feb-10 04:37PM | InPlay: Pharmasset files $150 mixed securities shelf offering in an S-3 filing Briefing.com |
| 29-Jan-10 04:00PM | Pharmasset Announces Exercise of Underwriter's Option PR Newswire |
| 28-Jan-10 09:35AM | PHARMASSET INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits EDGAR Online |
| 09:00AM | Pharmasset Prices Underwritten Offering of Common Stock PR Newswire |
| 27-Jan-10 04:49PM | Pharmasset Announces Proposed Public Offering of Common Stock PR Newswire |
| 25-Jan-10 04:31PM | PHARMASSET INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online |
| 21-Jan-10 07:00AM | Pharmasset Initiates Phase 2a Trial with PSI-7977, a Chirally Pure Isomer of PSI-7851 PR Newswire |
| 08-Jan-10 07:00AM | Pharmasset to Present at the 28th Annual JPMorgan Healthcare Conference PR Newswire |
| 17-Dec-09 11:15AM | Anadys hepatitis C drug meets key study goals AP |
| 16-Dec-09 02:33PM | Achillion shares rise on hepatitis C drug data AP |
| 03-Dec-09 01:04PM | PHARMASSET INC Financials EDGAR Online Financials |
| 01-Dec-09 05:24PM | PHARMASSET INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online |
| 26-Nov-09 09:23AM | New Star Analyst Rankings for Pharmasset, Inc. StarMine |
| 25-Nov-09 04:30PM | Pharmasset Reports Fiscal Year End 2009 Financial Results PR Newswire |
| 04:16PM | PHARMASSET INC Files SEC form 10-K, Annual Report EDGAR Online |
| 23-Nov-09 01:56PM | Pharmasset: hepatitis C drug trial will continue AP |
| 06:24AM | Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C PR Newswire |
| 17-Nov-09 10:56AM | Isis Cholesterol Drug Effective, but Safety a Worry: BioBuzz at TheStreet.com -7.40% |
| 09:11AM | InterMune Hep C Drug Hit With Liver Tox Worry: BioBuzz at TheStreet.com |
| 09-Nov-09 04:00PM | Pharmasset to Present at Lazard Capital Markets Healthcare Conference PR Newswire |
| 01:54PM | Doc Offers Top Hep C Drug Picks: BioBuzz at TheStreet.com |
| 03-Nov-09 08:16AM | INFORM-1 Results: Robust Antiviral Suppression Achieved with Combination of Nucleoside Analog Polymerase Inhibitor RG7128 and Protease Inhibitor RG7227 PR Newswire +6.91% |
| 01-Nov-09 07:00PM | Pharmasset to Webcast an Investor Event from the AASLD Meeting PR Newswire |
| 06-Oct-09 07:00AM | Pharmasset Nominates PSI-879 as a New Nucleotide Analog Inhibitor of Hepatitis C for Preclinical Development PR Newswire +5.05% |
| 01-Oct-09 04:00PM | Pharmasset to Present at JMP Securities Healthcare Conference PR Newswire |
| 08-Sep-09 04:30PM | Pharmasset to Present at Four Upcoming Investor Conferences PR Newswire |
| 09:23AM | Premarket roundup: Starent Networks, Pharmasset AP |
| 08:46AM | Ahead of the Bell: Pharmasset AP |
| 02:11AM | Pharmasset upgraded by Robert W. Baird Briefing.com |
| 10-Aug-09 04:33PM | PHARMASSET INC Files SEC form 10-Q, Quarterly Report EDGAR Online |
| 04:30PM | Pharmasset Reports Fiscal Third Quarter 2009 Financial Results PR Newswire |
| 05-Aug-09 04:15PM | Pharmasset to Present at Canaccord Adams Conference PR Newswire |
| 04-Aug-09 04:34PM | PHARMASSET INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online |
| 31-Jul-09 07:00AM | Pharmasset Reports Positive Preliminary Antiviral Data With PSI-7851 for the Treatment of Hepatitis C PR Newswire |
| 07-Jul-09 07:00AM | Pharmasset Nominates PSI-938 as a New Nucleotide Analog Inhibitor of Hepatitis C for Preclinical Development PR Newswire |
| 17-Jun-09 11:36AM | PHARMASSET INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits EDGAR Online |
| 09-Jun-09 06:30AM | Pharmasset Initiates Phase 1b Multiple Ascending Dose Clinical Trial of PSI-7851 in Chronic Hepatitis C Patients PR Newswire |
| 02-Jun-09 04:00PM | Pharmasset to Present at Goldman Sachs and Needham Healthcare Conferences PR Newswire |
| 14-May-09 04:32PM | PHARMASSET INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online |
| 04:00PM | Pharmasset to Present at Deutsche Bank Healthcare Conference PR Newswire |
| 11-May-09 04:49PM | PHARMASSET INC Files SEC form 10-Q, Quarterly Report EDGAR Online +6.08% |
| 04:43PM | Pharmasset Reports Fiscal Second Quarter 2009 Financial Results PR Newswire |
| 30-Apr-09 02:47PM | Sequenom Fallout Hits Hedge Funds at TheStreet.com -10.09% |
| 02:47PM | Sequenom Fallout Hits Hedge Funds at TheStreet.com |
| 11:06AM | Sequenom's Bombshell at Seeking Alpha |
| 29-Apr-09 04:41PM | PHARMASSET INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online +10.85% |
| 27-Apr-09 09:43AM | Hepatitis C Updates From EASL Liver Confab at TheStreet.com |
| 25-Apr-09 12:30PM | Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen PR Newswire |
| 24-Apr-09 07:35PM | Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C PR Newswire +7.36% |
| 23-Apr-09 12:00PM | Anadys Stock Falls on Hep C Data at TheStreet.com -5.43% |
| 11:49AM | Anadys Stock Rises on Hep C Data at TheStreet.com |
| 22-Apr-09 04:32PM | PHARMASSET INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online |
| 20-Apr-09 10:19PM | [$$] Swift Energy, Pharmasset, S&T Join the Retreat at The Wall Street Journal Online -9.95% |
| 10:38AM | UPDATE - Pharmasset stops hepatitis B trial, shares drop at Reuters |
| 08:23AM | Pharmasset cancels hepatitis drug development AP |
| 08:11AM | UPDATE - Pharmasset stops hepatitis B trial, shares sink at Reuters |
| 07:00AM | Pharmasset Voluntarily Halts Clinical Studies with Clevudine in Hepatitis B Infected Patients PR Newswire |
| 31-Mar-09 07:00AM | Pharmasset Initiates First Time in Human Study of PSI-7851 for the Treatment of Hepatitis C (HCV) PR Newswire |
| 30-Mar-09 09:02AM | Pharmasset to Present at Two Upcoming Investor Conferences PR Newswire |
| 19-Mar-09 10:31AM | Vertex Hep C Drug Improves Cure Rate in Study at TheStreet.com -6.67% |
| 03-Mar-09 04:15PM | Pharmasset to Present at Two Upcoming Investor Conferences PR Newswire +14.91% |
| 26-Feb-09 02:45PM | Wednesday's Biggest Stock Stars at Motley Fool |
| 09-Feb-09 04:54PM | Pharmasset Reports Fiscal First Quarter 2009 Financial Results PR Newswire |
| 04:31PM | PHARMASSET INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online |
| 06-Feb-09 07:13AM | Biotechnology: The New Defensive Sector That's Set to Rise? at Seeking Alpha |
| 05-Feb-09 04:26PM | PHARMASSET INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits EDGAR Online |
| 30-Jan-09 03:46PM | Investors to buy nearly $46M of Pharmasset stock AP +8.99% |
| 10:26AM | PHARMASSET INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits EDGAR Online |
| 09:51AM | Pharmasset Announces $45.5 Million Registered Direct Offering of Common Stock PR Newswire |
| 22-Jan-09 04:50PM | PHARMASSET INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online |
| 21-Jan-09 04:30PM | PHARMASSET INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Stateme EDGAR Online |
| 14-Jan-09 04:22PM | PHARMASSET INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online -6.84% |
| 12-Jan-09 04:21PM | Bristol-Myers to Buy Rights to Hep C Drug at TheStreet.com |
| 06:00AM | Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients PR Newswire |
| 08-Jan-09 09:29AM | Pharmasset to Present at the 27th Annual JPMorgan Healthcare Conference PR Newswire |
| 18-Dec-08 04:20PM | PHARMASSET INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligat EDGAR Online +8.07% |
| 11-Dec-08 06:09PM | Pharmasset Reports Fiscal Year End 2008 Financial Results PR Newswire |
| 04:22PM | PHARMASSET INC Files SEC form 10-K, Annual Report EDGAR Online |
| 12-Nov-08 03:57PM | Health Winners & Losers: Vivus at TheStreet.com +7.20% |
| 10-Nov-08 06:45AM | Pharmasset to Present at Two Upcoming Investor Conferences PR Newswire |
| 05:00AM | Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C PR Newswire |
| 03-Nov-08 02:26AM | Vertex Again Key Player at Hep C Meeting at TheStreet.com |
| 28-Oct-08 07:30AM | Pharmasset to Webcast an Investor Event from the AASLD Meeting PR Newswire |
| 08-Oct-08 07:30AM | Pharmasset to Present at the Natixis Bleichroeder Hidden Gems Conference on Monday, October 13th PR Newswire |
| 06-Oct-08 07:30AM | Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications PR Newswire -8.28% |
| 01-Oct-08 07:30AM | Pharmasset to Present at the JMP Securities Healthcare Focus Conference on Monday, October 6th PR Newswire |
| 26-Sep-08 04:05PM | InterMune Previews a Coming Attraction at Motley Fool |
| 17-Sep-08 07:30AM | Pharmasset to Present at the UBS Global Life Sciences Conference on Wednesday, September 24th PR Newswire -5.45% |
| 08-Sep-08 07:00AM | Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders PR Newswire |
| 05-Sep-08 12:00PM | Pharmasset to Present at the Upcoming Citibank and Morgan Stanley Investor Conferences PR Newswire |
| 20-Aug-08 03:58PM | Telaprevir Tests Its Luck at Motley Fool |
| 15-Aug-08 10:09AM | Biotech-Stock Mailbag: Genentech at TheStreet.com |
| 10:09AM | Biotech-Stock Mailbag: Genentech at TheStreet.com |
| 14-Aug-08 04:39PM | PHARMASSET INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online |
| 04:08PM | PHARMASSET INC Files SEC form 10-Q, Quarterly Report EDGAR Online |
| 04:01PM | Pharmasset Reports Financial Results for Quarter Ended June 30, 2008 PR Newswire |
| 13-Aug-08 04:56PM | PHARMASSET INC Files SEC form 8-K, Entry into a Material Definitive Agreement EDGAR Online |
| 08-Aug-08 04:14PM | Pharmasset to Present at the Canaccord Adams Global Growth Conference on Tuesday, August 12th PR Newswire +5.65% |
| 05-Aug-08 01:39PM | UPDATE - Pharmasset: hepatitis C drug positive in early stage at Reuters +9.45% |
| 08:55AM | Pharmasset drug passes early-stage goal AP |
|
|
| Pharmasset, Inc., a clinical-stage pharmaceutical company, focuses on discovering, developing, and commercializing novel drugs to treat viral infections. Its primary focus is on the development of nucleoside/tide analogs as oral therapeutics for the treatment of chronic hepatitis C virus (HCV) infection; and Racivir for the treatment of human immunodeficiency virus (HIV) infection. The company has three product candidates under development, which include RG7128, a HCV nucleoside polymerase inhibitor that is in Phase IIb clinical trial; PSI-7851, a HCV nucleotide polymerase inhibitor that completed Phase I clinical trial; and Racivir, which completed Phase II clinical trial, for the treatment of HIV. It has strategic collaboration agreement with F. Hoffmann-LaRoche Ltd. and Hoffmann-La Roche Inc. for the development of PSI-6130 and its products, including RG7128. The company also has collaboration and licensing agreements with University of Cincinnati; Apath, LLC; Emory University; Bukwang Pharm. Co., Ltd; University of Georgia Research Foundation, Inc. and Yale University; and Boehringer Ingelheim Chemicals, Inc. Pharmasset, Inc. was founded in 1998 and is based in Princeton, New Jersey. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Carney William J | Director | Jan 25 | Option Exercise | 3.97 | 7,500 | 29,775 | 68,666 | Jan 28 04:01 PM | | PRICE FREDRIC D | Director | Dec 04 | Option Exercise | 5.45 | 1,666 | 9,071 | 28,998 | Dec 07 01:57 PM | | QVT Associates GP LLC | 10% Owner | Sep 24 | Sale | 20.88 | 800,000 | 16,704,000 | 2,793,274 | Sep 24 07:04 PM | | QVT Associates GP LLC | 10% Owner | Sep 23 | Sale | 22.41 | 10,000 | 224,100 | 3,593,274 | Sep 24 07:04 PM | | QVT Associates GP LLC | 10% Owner | Sep 22 | Sale | 22.95 | 100,000 | 2,295,000 | 3,603,274 | Sep 24 07:04 PM | | OTTO MICHAEL | Exec.VP,Pharm.Research | Sep 18 | Option Exercise | 3.87 | 40,000 | 154,800 | 59,500 | Sep 25 11:04 AM | | OTTO MICHAEL | Exec.VP,Pharm.Research | Sep 18 | Sale | 21.93 | 40,000 | 877,061 | 2,410 | Sep 25 11:04 AM | | PRICE FREDRIC D | Director | Sep 02 | Option Exercise | 5.45 | 1,666 | 9,071 | 27,332 | Sep 03 04:33 PM | | PRICE FREDRIC D | Director | Jun 01 | Option Exercise | 5.45 | 21,666 | 117,971 | 25,666 | Jun 02 01:10 PM | | INOUYE MICHAEL K | Director | Feb 27 | Buy | 10.10 | 1,250 | 12,625 | 4,500 | Mar 02 01:49 PM | | INOUYE MICHAEL K | Director | Feb 26 | Buy | 10.64 | 1,250 | 13,297 | 3,250 | Mar 02 01:49 PM | | LUBETKIN PAUL | Executive VP & General Counsel | Feb 25 | Buy | 10.52 | 500 | 5,259 | 500 | Feb 26 12:26 PM |
|
|
|
|
|
|
